Home > Healthcare > Drug Device Combination > Drug Filled Devices > U.S. Contraceptives Market

U.S. Contraceptives Market Share

Report ID: GMI11769
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

U.S. Contraceptives Market Share

The market is highly competitive, with several key players dominating the landscape. Long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and contraceptive implants, have gained substantial market traction due to their high efficacy and long-term use. In addition to LARCs, the oral contraceptive pills segment remains one of the most widely used forms of birth control.

However, the increasing availability of over-the-counter (OTC) options and telemedicine platforms, such as Nurx and SimpleHealth, is reshaping the market by providing easier access to contraceptives. The growth of e-commerce and online prescription services has also captured a significant portion of the market, particularly among younger consumers, contributing to the diversification of market share across different segments.

U.S. Contraceptives Market Companies

Some of the eminent market participants operating in the U.S. Contraceptives industry include:

Allergan (AbbVie, Inc.)
Ani Pharmaceuticals
Bayer AG
CooperSurgical Inc
Church & Dwight Co, Inc.
Johnson & Johnson
Mayer Laboratories, Inc.
Merck & Co., Inc.
Meril Life Sciences Pvt. Ltd.
Perrigo Company
Pfizer, Inc.
Pregna International Ltd.
Reckitt Benckiser Group Plc.
Teva Pharmaceuticals Industries Ltd.
Veru Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market was valued at approximately USD 7 billion in 2023 and is projected to grow at a CAGR of 7.2% from 2024 to 2032, driven by the demand for various birth control methods such as condoms, IUDs, vaginal rings, and pills.

The drugs segment dominated the market with a revenue of around USD 3.8 billion in 2023. Contraceptive drugs, when used correctly and consistently, provide a reliable method of birth control, allowing individuals to plan and space pregnancies according to their personal preferences and circumstances.

The East South Central region's market generated a revenue of USD 1.7 billion in 2023 and is anticipated to grow at a CAGR of 7.9% from 2024 to 2032, driven by high rates of unintended pregnancies and increased awareness about family planning.

Key players include Allergan (AbbVie, Inc.), Ani Pharmaceuticals, Bayer AG, CooperSurgical Inc, Church & Dwight Co, Inc., Johnson & Johnson, and Mayer Laboratories, Inc.